Beyond cyclosporine A: Conformation-dependent passive membrane permeabilities of cyclic peptide natural products

Future Medicinal Chemistry

Volumn 7, Issue 16, 2015, Pages 2121-2130

  Ahlbach, Christopher L ^a   Lexa, Katrina W ^b   Bockus, Andrew T ^a   Chen, Valerie ^a   Crews, Phillip ^a   Jacobson, Matthew P ^b   Lokey, R Scott ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cyclic peptide; cyclosporine; PAMPA; permeability

Indexed keywords

CYCLOASPEPTIDE A; CYCLOPEPTIDE; CYCLOSPORIN A; CYCLOSPORIN B; CYCLOSPORIN D; CYCLOSPORINE C; CYCLOSPORINE E; CYCLOSPORINE H; DAPTOMYCIN; DESMETHYLDESTRUXIN B; DESTRUXIN A; DESTRUXIN B; DESTRUXIN B2; DESTRUXIN E CHLOROHYDRIN; DESTRUXIN E2 CHLOROHYDRIN; DIDEMNIN A; ENNIATIN; ENNIATIN H; ENNIATIN I; ENNIATIN J1; ENNIATIN MK1; GUANGOMIDE A; GUANGOMIDE B; MIRABAMIDE C; PATELLAMIDE C; SCLEROTIOTIDE F; SCYTALIDAMIDE; TENTOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERRUCAMIDE B; ARTIFICIAL MEMBRANE; BIOLOGICAL PRODUCT; CYCLOSPORIN;

ALGORITHM; ARTICLE; ARTIFICIAL MEMBRANE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG PENETRATION; HYDROGEN BOND; HYDROPHOBICITY; MEMBRANE PERMEABILITY; PREDICTION; PRIORITY JOURNAL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECTS; HUMAN;

BIOLOGICAL PRODUCTS; CELL MEMBRANE PERMEABILITY; CYCLOSPORINE; HUMANS; MEMBRANES, ARTIFICIAL; PEPTIDES, CYCLIC;

EID: 84942253842     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.78     Document Type: Article

References (59)

1. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat. Rev. Drug Discov. 5(12), 993-996 (2006).
2. Malovannaya A, Lanz RB, Jung SY et al. Analysis of the human endogenous coregulator complexome. Cell 145(5), 787-799 (2011).
3. Colby DW, Chu Y, Cassady JP et al. Potent inhibition of Huntingtin aggregation and cytotoxicity by a disulfide bondfree single-domain intracellular antibody. Proc. Natl Acad. Sci. USA 101(51), 17616-17621 (2004).
4. Kenne E, Renne T. Factor XII: A drug target for safe interference with thrombosis and inflammation. Drug Discov. Today 19(9), 1459-1464 (2014).
5. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov. Today 17(17-18), 954-963 (2012).
6. Passioura T, Katoh T, Goto Y, Suga H. Selection-based discovery of druglike macrocyclic peptides. Annu. Rev. Biochem. 83, 727-752 (2014).
7. Kawamoto SA, Coleska A, Ran X, Yi H, Yang CY, Wang S. Design of triazole-stapled BCL9 alpha-helical peptides to target the beta-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. J. Med. Chem. 55(3), 1137-1146 (2012).
8. Madden MM, Muppidi A, Li Z, Li X, Chen J, Lin Q. Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition. Bioorg. Med. Chem. Lett. 21(5), 1472-1475 (2011).
9. Moellering RE, Cornejo M, Davis TN et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462(7270), 182-188 (2009).
10. Liu B, Kodadek T. Investigation of the relative cellular permeability of DNA-binding pyrrole-imidazole polyamides. J. Med. Chem. 52(15), 4604-4612 (2009).
11. Gavenonis J, Sheneman BA, Siegert TR, Eshelman MR. Comprehensive analysis of loops at protein-protein interfaces for macrocycle design. Nat. Chem. Biol. 10(9), 716-722 (2014).
12. Passioura T, Suga H. Flexizyme-mediated genetic reprogramming as a tool for noncanonical peptide synthesis and drug discovery. Chem. Eur. J. 19(21), 6530-6536 (2013).
13. Quartararo JS, Wu P, Kritzer JA. Peptide bicycles that inhibit the Grb2 SH2 domain. Chembiochem 13(10), 1490-1496 (2012).
14. Wrighton NC, Farrell FX, Chang R et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273(5274), 458-464 (1996).
15. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44(1), 235-249 (2000).
16. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery [mdash] an underexploited structural class. Nat. Rev. Drug Discov. 7(7), 608-624 (2008).
17. Mallinson J, Collins I. Macrocycles in new drug discovery. Future Med. Chem. 4(11), 1409-1438 (2012).
18. Heinis C. Drug discovery: tools and rules for macrocycles. Nat. Chem. Biol. 10(9), 696-698 (2014).
19. Villar EA, Beglov D, Chennamadhavuni S et al. How proteins bind macrocycles. Nat. Chem. Biol. 10(9), 723-731 (2014).
20. Giordanetto F, Kihlberg J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57(2), 278-295 (2013).
21. Bockus AT, McEwen CM, Lokey RS. Form and function in cyclic peptide natural products: A pharmacokinetic perspective. Curr. Top. Med. Chem. 13(1873-4294), 821-836 (2013).
22. Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K. Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine. Drug Metab. Pharmacokinet. 20(5), 324-330 (2005).
23. Guimaraes CR, Mathiowetz AM, Shalaeva M, Goetz G, Liras S. Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation. J. Chem. Inf. Comput. Sci. 52(4), 882-890 (2012).
24. Doak BC, Over B, Giordanetto F, Kihlberg J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 21(9), 1115-1142 (2014).
25. Leung SS, Mijalkovic J, Borrelli K, Jacobson MP. Testing physical models of passive membrane permeation. J. Chem. Inf. Comput. Sci. 52(6), 1621-1636 (2012).
26. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41(7), 1007-1010 (1998).
27. White TR, Renzelman CM, Rand AC et al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat. Chem. Biol. 7(11), 810-817 (2011).
28. Senel FM, Yildirim S, Karakayali H, Moray G, Haberal M. Comparison of Neoral and Sandimmun for induction and maintenance immunosuppression after kidney transplantation. Transplant Int. 10(5), 357-361 (1997).
29. Small-Molecule Drug Discovery Suite, QikProp. Schrödinger LCC, NY, USA (2015).
30. R Core Team. R: A Language and Environment for Statistical Computing.R Foundation for Statistical Computing, Vienna, Austria (2013).
31. Marrink SJ, Jahnig F, Berendsen HJ. Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations. Biophys. J. 71(2), 632-647 (1996).
32. Ashwood VA, Field MJ, Horwell DC et al. Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist. J. Med. Chem. 44(14), 2276-2285 (2001).
33. Sasaki S, Cho N, Nara Y et al. Discovery of a thieno[2,3-d] pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: A highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. J. Med. Chem. 46(1), 113-124 (2003).
34. Rezai T, Yu B, Millhauser G, Jacobson M, Lokey R. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc. 128(8), 2510-2511 (2006).
35. Rezai T, Bock J, Zhou M, Kalyanaraman C, Lokey R, Jacobson M. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: Successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc. 128(43), 14073-14080 (2006).
36. Ettorre A, D'Andrea P, Mauro S et al. hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg. Med. Chem. Lett. 21(6), 1807-1809 (2011).
37. Ovadia O, Greenberg S, Chatterjee J et al. The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol. Pharmacol. 8(2), 479-487 (2011).
38. Rafi S, Hearn B, Vedantham P, Jacobson M, Renslo A. Predicting and improving the membrane permeability of peptidic small molecules. J. Med. Chem. 55(7), 3163-3169 (2012).
39. Chatterjee J, Mierke D, Kessler H. N-methylated cyclic pentaalanine peptides as template structures. J. Am. Chem. Soc. 128(47), 15164-15172 (2006).
40. Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: A new perspective in medicinal chemistry. Acc. Chem. Res. 41(10), 1331-1342 (2008).
41. Bockus AT, Lexa KW, Pye CR et al. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J. Med. Chem. doi:10.1021/acs.jmedchem.5b00128 (2015) (Epub ahead of print).
42. Naganawa H, Takita T, Suzuki A, Tamura S, Lee S, Izumiya N. Conformational studies of destruxins, insecticidal cyclodepsipeptides. Agric. Biol. Chem. 40(11), 2223-2229 (1976).
43. Yeh SF, Pan W, Ong G-T et al. Study of structure-activity correlation in destruxins, a class of cyclodepsipeptides possessing suppressive effect on the generation of hepatitis B virus surface antigen in human hepatoma cells. Biochem. Biophys. Res. Commun. 229(1), 65-72 (1996).
44. Loosli H-R, Kessler H, Oschkinat H, Weber H-P, Petcher TJ, Widmer A. Peptide conformations. Part 31. The conformation of cyclosporin a in the crystal and in solution. Helv. Chim. Acta 68(3), 682-704 (1985).
45. Kessler H, Gehrke M, Lautz J, Kock M, Seebach D, Thaler A. Complexation and medium effects on the conformation of cyclosporin A studied by NMR spectroscopy and molecular dynamics calculations. Biochem. Pharmacol. 40(1), 169-173 (1990).
46. O'Donohue MF, Burgess AW, Walkinshaw MD, Treutlein HR. Modeling conformational changes in cyclosporin A. Protein Sci. 4(10), 2191-2202 (1995).
47. Bodack LA, Freedman TB, Chowdhry BZ, Nafie LA. Solution conformations of cyclosporins and magnesium-cyclosporin complexes determined by vibrational circular dichroism. Biopolymers 73(2), 163-177 (2004).
48. Qu ZW, Zhu H, May V. Unambiguous assignment of vibrational spectra of cyclosporins A and H. J. Phys. Chem. A 114(36), 9768-9773 (2010).
49. Efimov SV, Karataeva FK, Aganov AV, Berger S, Klochkov VV. Spatial structure of cyclosporin A and insight into its flexibility. J. Mol. Struct. 1036(0), 298-304 (2013).
50. Ruegger A, Kuhn M, Lichti H et al. [Cyclosporin A, a peptide metabolite from trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity]. Helv. Chim. Acta 59(4), 1075-1092 (1976).
51. Pohl E, Sheldrick GM, Bölsterli JJ, Kallen J, Traber R, Walkinshaw MD. Crystal structure and packing of isocyclosporin A. Helv. Chim. Acta 79(6), 1635-1642 (1996).
52. Hewitt WM, Leung SS, Pye CR et al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. J. Am. Chem. Soc. 137(2), 715-721 (2015).
53. Nielsen DS, Hoang HN, Lohman RJ et al. Improving on nature: making a cyclic heptapeptide orally bioavailable. Angew. Chem. Int. Ed. Engl. 53(45), 12059-12063 (2014).
54. Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M. Epik: A software program for pK(a) prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21(12), 681-691 (2007).
55. Jeffery JR. Cyclosporine analogues. Clin. Biochem. 24(1), 15-21 (1991).
56. Oliyai R, Safadi M, Meier PG, Hu MK, Rich DH, Stella VJ. Kinetics of acid-catalyzed degradation of cyclosporin A and its analogs in aqueous solution. Int. J. Pept. Protein Res. 43(3), 239-247 (1994).
57. Bohumil K, Alexandr J, Svetlana P et al. Crystal structures of cyclosporin derivatives: O-Acetyl-(4R)-4-(E-2-butyl)-4,Ndimethyl-L-threonyl-cyclosporin A and O-Acetyl-(4R)-4-[E-2-(4-bromobutyl)]-4,N-dimethyl-L-threonyl-cyclosporin A. Collect. Czech. Chem. Commun. 64(1), 89-98 (1999).
58. Michal Hušák BK, Martin Buchta, Ladislav Cvak, Alexandr Jegorov. Crystal structure of cyclosporin E. Collect. Czech. Chem. Commun. 63(1), 115-120 (1998).
59. Rand AC, Leung SSF, Eng H et al. Optimizing PK properties of cyclic peptides: The effect of side chain substitutions on permeability and clearance. Med. Chem. Comm. 3(10), 1282-1289 (2012).